Erythropoiesis-stimulating agent (ESA) Pregnancy: Considered safe — large safety dataset in CKD pregnancy. Adjust dose for increased erythropoiesis demand of pregnancy.

Darbepoetin alfa

Brand names: Aranesp

Adult dose

Dose: Renal anaemia (CKD-on-dialysis or pre-dialysis): start 0.45 mcg/kg SC/IV weekly, OR 0.75 mcg/kg every 2 weeks; titrate by 25% increments every 4 weeks based on Hb response. Cancer chemotherapy-induced anaemia: 2.25 mcg/kg SC weekly OR 500 mcg every 3 weeks; only if Hb <100 g/L AND patient on chemotherapy expected to continue ≥2 months.

Route: Subcutaneous / IV

Frequency: Weekly, fortnightly, or every 3 weeks (longer half-life than epoetin α/β)

Target Hb 100–120 g/L (ESC 2018); avoid >120 g/L (CHOIR / TREAT trials — increased CV risk and stroke). Always exclude/correct iron deficiency (TSAT <20% or ferritin <100 in CKD), B12, folate before start.

Dose adjustments

Renal

Indicated for renal anaemia. No specific dose change for renal function.

Hepatic

Caution; no specific adjustment.

Clinical pearls

Longer half-life than epoetin alfa/beta (25 hr vs 8 hr SC) → less frequent dosing (weekly to every 3 weeks) → adherence advantage in pre-dialysis CKD.
Target Hb 100–120 g/L. Never aim above 120 g/L — CHOIR (NEJM 2006), CREATE, TREAT trials all showed increased CV events at higher targets.
Iron deficiency is the most common cause of ESA hyporesponse in CKD: TSAT <20% or ferritin <100 µg/L → IV iron BEFORE escalating ESA dose.
Pure red cell aplasia (PRCA): if Hb falls during ESA therapy with reticulocytopenia → check anti-erythropoietin antibodies; specialist haematology.
Cancer use — strict NICE criteria: Hb <100 g/L on chemotherapy, expected ≥2 month chemo continuation, target Hb only to 110 g/L. Discuss tumour progression risk explicitly with patient.
Self-administer SC at home for stable CKD patients — patient training programmes widely available.

Contraindications

Uncontrolled hypertension
Pure red cell aplasia from prior ESA
Hypersensitivity
Active malignancy with curative intent (cancer indication only — survival concern in head & neck and breast cancer trials with high Hb targets)

Side effects

Hypertension (very common — pre-treatment HTN should be controlled; ESAs raise BP 5–10 mmHg)
Thromboembolism — VTE, stroke, MI (especially Hb >120 g/L)
Pure red cell aplasia (rare — antibody-mediated, mostly historical with epoetin α SC formulations)
Headache
Injection-site reactions
Flu-like symptoms
Hyperkalaemia (in CKD, transient)
Seizures (rare — usually rapid Hb rise)
Tumour progression / shortened survival in cancer (especially aiming Hb >120 g/L)

Interactions

ACEi / ARB: may blunt erythropoietic response (mechanism unclear)
IV iron: synergistic — most CKD patients on ESA require concurrent IV iron
Heparin (during dialysis): may need heparin dose increase as erythropoiesis ↑ blood viscosity

Monitoring

Hb every 2 weeks during titration, then every 4 weeks; TSAT and ferritin every 3 months; BP weekly initially; K+ in CKD; pregnancy test as appropriate

Reference: BNF 90; SmPC Aranesp; KDIGO Anaemia in CKD 2012; NICE NG8 (Anaemia in CKD 2015); CHOIR NEJM 2006;355:2085; TREAT NEJM 2009;361:2019. Verify against your local formulary and the latest BNF before prescribing.

Curated clinical cross-links plus same-class fallbacks.

Pathways